公开(公告)号：WO2009136382A2

公开(公告)日：2009-11-12

申请号：PCT/IB2009051915

申请日：2009-05-08

Applicant: ABBOTT GMBH & CO KG ,  ABBOTT LAB ,  GU JIJIE ,  HSIEH CHUNG-MING ,  WU ZHEN ,  DIGIAMMARINO ENRICO L ,  LUO FENG ,  FOX GERARD B ,  HARLAN JOHN E ,  SCHMIDT MARTIN ,  LOEBBERT RALF ,  MUELLER REINHOLD ,  EBERT ULRICH ,  NIMMRICH VOLKER

Inventor： GU JIJIE ,  HSIEH CHUNG-MING ,  WU ZHEN ,  DIGIAMMARINO ENRICO L ,  LUO FENG ,  FOX GERARD B ,  HARLAN JOHN E ,  SCHMIDT MARTIN ,  LOEBBERT RALF ,  MUELLER REINHOLD ,  EBERT ULRICH ,  NIMMRICH VOLKER

IPC: C12N15/12 ,  C12N5/00 ,  C12N7/00

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/464 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C12P21/005

Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid ß and advanced glycation-end-products.

Abstract translation: 本申请涉及分离的蛋白质，特别是单克隆抗体，特别是结合RAGE蛋白质的CDR-移植的人源化抗体。 具体地说，这些抗体具有抑制RAGE与其各种配体结合的能力。 本申请中描述的抗体或其部分可用于治疗由RAGE的病理生理学配体表征或诱导的疾病或病症，例如错折叠蛋白，如淀粉样蛋白β和晚期糖基化终产物。

公开(公告)号：WO2008064292A2

公开(公告)日：2008-05-29

申请号：PCT/US2007085349

申请日：2007-11-21

Applicant: ABBOTT LAB ,  MEZLER MARIO ,  MOELLER ACHIM ,  MUELLER REINHOLD ,  MUELLER BERNHARD K ,  GHAYUR TARIQ ,  BARLOW EVE H ,  SCHMIDT MARTIN ,  MEYER AXEL ,  TEUSCH NICOLE

Inventor： MEZLER MARIO ,  MOELLER ACHIM ,  MUELLER REINHOLD ,  MUELLER BERNHARD K ,  GHAYUR TARIQ ,  BARLOW EVE H ,  SCHMIDT MARTIN ,  MEYER AXEL ,  TEUSCH NICOLE

IPC: A61K39/395

CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K2039/505 ,  C07H21/00 ,  C07K16/2863 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

Abstract translation: 本发明涉及结合Nogo-66受体的分离的蛋白质，特别是单克隆抗体。 具体地说，这些抗体具有抑制Nogo-66受体的天然配体结合并中和Nogo-66受体的能力。 本发明的这些抗体或其部分可用于检测NgR和抑制NgR活性，例如在患有NgR或Nogo-66活性有害的病症的人中。

公开(公告)号：EP2091563A4

公开(公告)日：2010-12-15

申请号：EP07854735

申请日：2007-11-21

Applicant: ABBOTT LAB

Inventor： MEZLER MARIO ,  MOELLER ACHIM ,  MUELLER REINHOLD ,  MUELLER BERNHARD K ,  GHAYUR TARIQ ,  BARLOW EVE H ,  SCHMIDT MARTIN ,  MEYER AXEL ,  TEUSCH NICOLE

IPC: A61K39/395

CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K2039/505 ,  C07H21/00 ,  C07K16/2863 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

公开(公告)号：CA2715456C

公开(公告)日：2020-10-27

申请号：CA2715456

申请日：2009-02-27

Applicant: ABBOTT GMBH & CO KG ,  ABBOTT LAB

Inventor： MUELLER BERNHARD K ,  SCHMIDT MARTIN ,  BARLOW EVE H ,  LEDDY MARY R ,  HSIEH CHUNG-MING ,  BARDWELL PHILLIP D

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/46

Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but not limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.

公开(公告)号：NZ587198A

公开(公告)日：2012-10-26

申请号：NZ58719809

申请日：2009-02-27

Applicant: ABBOTT GMBH & CO KG ,  ABBOTT LAB

Inventor： MULLER BERNHARD K ,  SCHMIDT MARTIN ,  BARLOW EVE H ,  LEDDY MARY R ,  HSIEH CHUNG-MING ,  BARDWELL PHILLIP D

IPC: C07K16/22 ,  A61K39/395

Abstract: Disclosed is an isolated antibody comprising an antigen binding domain, said antibody capable of binding an epitope of a RGM molecule, said antigen binding domain comprising a heavy chain variable domain having at least three complementary determining regions and a light chain variable domain having at least three complementary determining regions, wherein the at least three complementary determining regions of the heavy chain variable domain have the amino acid sequence of SEQ ID NO:57, SEQ ID NO:58 and SEQ ID NO:59 and the at least three complementary determining regions of the light chain variable domain have the amino acid sequence of SEQ ID NO: 60, SEQ ID NO:61 and SEQ ID NO:62. Further disclosed is an isolated antibody comprising an antigen binding domain, said antibody capable of binding an epitope of a RGM molecule, said antigen binding domain comprising a heavy chain variable domain and a light chain variable wherein the heavy chain variable domain has the amino acid sequence selected from the group consisting of: SEQ ID NOS: 35, 36, 37, 38, 39, 40, 41, 42, 43, 47, 48, 49 and 50 and wherein the light chain variable domain has the amino acid sequence selected from the group consisting of SEQ ID NO:44, 45, 46, 51, 52, 53 and 54.

公开(公告)号：ECSP10010481A

公开(公告)日：2010-10-30

申请号：ECSP10010481

申请日：2010-09-13

Applicant: ABBOTT LAB ,  ABBOTT GMBH & CO KG

Inventor： MUELLER BERNHARD K ,  SCHMIDT MARTIN ,  BARLOW EVE H ,  LEDDY MARY R ,  HSIEH CHUNGMING ,  BARDWELL PHILLIP D

IPC: A61K39/395 ,  C07K16/22

Abstract: Proteínas aisladas, particularmente anticuerpos monoclonales, que se unen y neutralizan la proteína RGM A. Específicamente, estos anticuerpos tienen la capacidad de inhibir la unión de RGM A a su receptor y/o sus correceptores. Los anticuerpos de la invención, o sus porciones, son útiles para detectar RGM A e inhibir la actividad de RGM A, por ejemplo, en un ser humano afectado por un trastorno que incluye, no taxativamente, esclerosis múltiple, traumatismo cerebral en mamíferos, lesiones en la médula espinal, accidente cerebrovascular, enfermedades neurodegenerativas, y esquizofrenia.

公开(公告)号：AU2009218693A1

公开(公告)日：2009-09-03

申请号：AU2009218693

申请日：2009-02-27

Applicant: ABBOTT GMBH & CO KG ,  ABBOTT LAB

Inventor： SCHMIDT MARTIN ,  MULLER BERNHARD K ,  HSIEH CHUNG-MING ,  LEDDY MARY R ,  BARDWELL PHILLIP D ,  BARLOW EVE H

IPC: C07K16/22 ,  A61K39/395

Abstract: The subject invention relates to monoclonal antibodies which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or antigen binding fragments thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but not limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.

公开(公告)号：CA2670368A1

公开(公告)日：2008-05-29

申请号：CA2670368

申请日：2007-11-21

Applicant: ABBOTT LAB

Inventor： MUELLER REINHOLD ,  GHAYUR TARIQ ,  BARLOW EVE H ,  MUELLER BERNHARD K ,  TEUSCH NICOLE ,  SCHMIDT MARTIN ,  MEYER AXEL ,  MOELLER ACHIM ,  MEZLER MARIO

IPC: A61K39/395

Abstract: The subject invention relates to isolated proteins, particularly monoclon al antibodies, which bind to the Nogo-66 receptor. Specifically, these antib odies have the ability to inhibit the binding of the natural ligand of the N ogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or por tions thereof of the invention are useful for detecting NgR and for inhibiti ng NgR activity, for example in a human suffering from a disorder in which N gR or Nogo-66 activity is detrimental.

公开(公告)号：ES2609924T3

公开(公告)日：2017-04-25

申请号：ES07854735

申请日：2007-11-21

Applicant: ABBOTT LAB ,  ABBVIE DEUTSCHLAND

Inventor： MEZLER MARIO ,  MOELLER ACHIM ,  MUELLER REINHOLD ,  MUELLER BERNHARD K ,  GHAYUR TARIQ ,  BARLOW EVE H ,  SCHMIDT MARTIN ,  MEYER AXEL ,  TEUSCH NICOLE

IPC: C07K16/28

Abstract: Un anticuerpo monoclonal neutralizante aislado, o un fragmento de unión al antígeno del mismo, que interactúan específicamente al menos con un epítopo del receptor de Nogo-66, donde el anticuerpo monoclonal neutralizante aislado, o un fragmento de unión al antígeno del mismo , comprende una secuencia que comprende una región variable de cadena pesada (región VH) que comprende SEQ ID NO: 3 y una secuencia que comprende una región variable de cadena ligera (región VL) que comprende SEQ ID NO: 4, o una secuencia que comprende una región variable de cadena pesada (región VH) que comprende SEQ ID NO: 5 y una secuencia que comprende una región variable de cadena ligera (región VL) que comprende SEQ ID NO: 6.

公开(公告)号：SG188142A1

公开(公告)日：2013-03-28

申请号：SG2013010228

申请日：2009-05-08

Applicant: ABBOTT GMBH & CO KG ,  ABBOTT LAB

Inventor： GU JIJIE ,  HSIEH CHUNG-MING ,  WU ZHEN ,  DIGIAMMARINO ENRICO L ,  LUO FENG ,  FOX GERARD B ,  HARLAN JOHN E ,  SCHMIDT MARTIN ,  LOEBBERT RALF ,  MUELLER REINHOLD ,  EBERT ULRICH ,  NIMMRICH VOLKER

Abstract: The present application relates to isolated proteins, particularly monoclonal antibodies, in particular CDR-grafted, humanized antibodies which bind to RAGE protein. Specifically, these antibodies have the ability to inhibit the binding of RAGE to its various ligands. The antibodies or portions thereof of described in the present application are useful for treating a disease or disorder characterized by or induced by pathophysiological ligands of RAGE, for example missfolded proteins like amyloid and advanced glycation-end-products.No suitable figure